Aneurysmal subarachnoid hemorrhage remains a devastating condition with persistently high rates of early mortality and disability. While numerous prognostic models exist, the prognostic relevance of metabolic dysfunction in aneurysmal subarachnoid hemorrhage remains uncertain. We retrospectively analyzed 60 consecutive patients with subarachnoid hemorrhage admitted between 2022 and 2024. Metabolic syndrome and its components-including impaired glucose tolerance, insulin resistance, hypertension, dyslipidemia, and obesity-were evaluated within 24 hours of admission. The primary endpoint was poor functional outcome at discharge (modified Rankin Scale 3-6). Secondary endpoints included in-hospital complications and mortality. In adjusted ridge-penalized logistic regression analyses, impaired glucose tolerance (adjusted odds ratio 4.93, 95% confidence interval 1.39-17.4, p = 0.014) and World Federation of Neurological Surgeons grade ≥3 (adjusted odds ratio 5.12, 95% confidence interval 1.62-16.18, p = 0.006) independently predicted poor outcome. Insulin resistance was independently associated with in-hospital complications (adjusted odds ratio 4.05, 95% confidence interval 1.15-14.3, p = 0.030). Mortality was independently predicted by age (adjusted odds ratio 1.06, 95% confidence interval 1.01-1.12, p = 0.032), World Federation of Neurological Surgeons grade ≥3, and impaired glucose tolerance. The composite metabolic syndrome variable was not an independent predictor of any outcome. In conclusion, specific metabolic abnormalities- impaired glucose tolerance, insulin resistance, and hypertension-rather than metabolic syndrome appear to drive early prognosis after subarachnoid hemorrhage. Early metabolic profiling and individualized glucose control may help identify patients at risk and guide future interventional studies.
Özkara et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: